NVS Relative Valuation - Novartis AG

Watchlist Manager

Watchlist

Price: 148.09 USD 1.41% Market Closed

Market Cap: $299.8B

	Novartis AG NYSE:NVS	CH
	Microsaic Systems PLC LSE:MSYS	UK
	Swatch Group AG SIX:UHR	CH

Relative Value

The Relative Value of one NVS stock under the Base Case scenario is 145.59 USD. Compared to the current market price of 148.09 USD, Novartis AG is Overvalued by 2%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

NVS Relative Value

Base Case

Overvaluation 2%

Relative Value

Price

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
CH		Novartis AG NYSE:NVS	221.8B USD	5.1	20.6	12.8	16.4
US		Eli Lilly and Co NYSE:LLY	860.3B USD	13.2	41.7	28.1	30
US		Johnson & Johnson NYSE:JNJ	566.9B USD	6	21.1	14.7	18.1
CH		Roche Holding AG SIX:ROG	243.3B CHF	3.9	18.6	11.1	12.5
UK		AstraZeneca PLC LSE:AZN	215.5B GBP	4.9	28	15.6	21.9
US		Merck & Co Inc NYSE:MRK	282.6B USD	4.4	15.7	9.7	11.9
IE	E	Endo International PLC LSE:0Y5F	237.1B USD	102.3	-81.1	375.3	941.3
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.3	7.6	8.9
US		Pfizer Inc NYSE:PFE	153.4B USD	2.4	19.6	7.6	10.1
US		Bristol-Myers Squibb Co NYSE:BMY	114.7B USD	2.4	16.3	6.9	8.5
FR		Sanofi SA PAR:SAN	92.9B EUR	2	11.9	10	10

				Revenue Growth	P/S to Growth
CH		Novartis AG NYSE:NVS	Average P/S: 13.6 5.1	5%	1
US		Eli Lilly and Co NYSE:LLY	13.2	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6	6%	1
CH		Roche Holding AG SIX:ROG	3.9	4%	1
UK		AstraZeneca PLC LSE:AZN	4.9	7%	0.7
US		Merck & Co Inc NYSE:MRK	4.4	5%	0.9
IE	E	Endo International PLC LSE:0Y5F	102.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	2%	1.7
US		Pfizer Inc NYSE:PFE	2.4	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A
FR		Sanofi SA PAR:SAN	2	5%	0.4

				Earnings Growth	PEG
CH		Novartis AG NYSE:NVS	Average P/E: 20.4 20.6	14%	1.5
US		Eli Lilly and Co NYSE:LLY	41.7	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.1	7%	3
CH		Roche Holding AG SIX:ROG	18.6	14%	1.3
UK		AstraZeneca PLC LSE:AZN	28	26%	1.1
US		Merck & Co Inc NYSE:MRK	15.7	14%	1.1
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -81.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.3	1%	10.3
US		Pfizer Inc NYSE:PFE	19.6	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.3	16%	1
FR		Sanofi SA PAR:SAN	11.9	16%	0.7

				EBITDA Growth	EV/EBITDA to Growth
CH		Novartis AG NYSE:NVS	Average EV/EBITDA: 45.4 12.8	5%	2.6
US		Eli Lilly and Co NYSE:LLY	28.1	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.7	2%	7.4
CH		Roche Holding AG SIX:ROG	11.1	6%	1.8
UK		AstraZeneca PLC LSE:AZN	15.6	13%	1.2
US		Merck & Co Inc NYSE:MRK	9.7	3%	3.2
IE	E	Endo International PLC LSE:0Y5F	375.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.6	1%	7.6
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	6.9	-10%	N/A
FR		Sanofi SA PAR:SAN	10	19%	0.5

				EBIT Growth	EV/EBIT to Growth
CH		Novartis AG NYSE:NVS	Average EV/EBIT: 99.1 16.4	9%	1.8
US		Eli Lilly and Co NYSE:LLY	30	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.1	6%	3
CH		Roche Holding AG SIX:ROG	12.5	6%	2.1
UK		AstraZeneca PLC LSE:AZN	21.9	21%	1
US		Merck & Co Inc NYSE:MRK	11.9	6%	2
IE	E	Endo International PLC LSE:0Y5F	941.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.9	2%	4.5
US		Pfizer Inc NYSE:PFE	10.1	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.5	-7%	N/A
FR		Sanofi SA PAR:SAN	10	12%	0.8

Novartis AG
NYSE:NVS

Relative Value

Valuation Multiples

Multiples Across Competitors

NVS Competitors Multiples
Novartis AG Competitors

See Also

Company

Help

Tools

Stocks

Novartis AG NYSE:NVS

Relative Value

Valuation Multiples

Multiples Across Competitors

NVS Competitors Multiples Novartis AG Competitors

See Also

Company

Help

Tools

Stocks

Novartis AG
NYSE:NVS

NVS Competitors Multiples
Novartis AG Competitors